Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

65.36B

Market cap65.36B

Price-Earnings ratio

15.06

Price-Earnings ratio15.06

Dividend yield

0.59%

Dividend yield0.59%

Average volume

1.23M

Average volume1.23M

High today

$630.92

High today$630.92

Low today

$619.38

Low today$619.38

Open price

$622.04

Open price$622.04

Volume

835.90K

Volume835.90K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$514.79

52 Week low$514.79

Stock Snapshot

Regeneron(REGN) stock is priced at $623.43, giving the company a market capitalization of 65.36B. It carries a P/E multiple of 15.06 and pays a dividend yield of 0.59%.

During the trading session on 2026-06-24, Regeneron(REGN) shares reached a daily high of $630.92 and a low of $619.38. At a current price of $623.43, the stock is +0.7% higher than the low and still -1.2% under the high.

Trading volume for Regeneron(REGN) stock has reached 835.9K, versus its average volume of 1.23M.

The stock's 52-week range extends from a low of $514.79 to a high of $821.11.

REGN News

Simply Wall St 20h

Regeneron Pharmaceuticals Leans On Pipeline Promise As Undervaluation Case Stays In Focus

Regeneron Pharmaceuticals (REGN) has drawn investor attention after recent trading that leaves the stock down about 3% over the past month and roughly 18% over...

Seeking Alpha 1d

Regeneron myasthenia gravis therapy undergoes U.S. and EU review

The U.S. and European regulators have accepted Regeneron’s (REGN) marketing applications for cemdisiran, an experimental therapy developed with Alnylam Pharmace...

TipRanks 3d

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

RBC Capital keeps a Sector Perform rating and a $707 price target on Regeneron (REGN) but notes that the acquisition of Apogee Therapeutics (APGE) by AbbVie (AB...

Analyst ratings

74%

of 31 ratings

Buy

74.2%

Hold

25.8%

Sell

More REGN News

TipRanks 3d

Regeneron announces FDA, EMA accept cemdisiran submissions for review

Regeneron (REGN) announced that both the FDA and European Medicines Agency, or EMA, have accepted the regulatory applications for cemdisiran to treat adult pati...

TipRanks 6d

Regeneron Advances First-in-Human Myeloma Combo Trial, Keeping Oncology Pipeline in Focus

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Pr...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.